BioSpace News Archive

Zucara Therapeutics Inc., today announced that its positive proof-of-concept data has enabled the Company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.

Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million.

Gain Therapeutics, Inc. today announced the presentation of new preclinical data at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT.

Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal second quarter 2023 financial results on Thursday, October 6, 2022, after the market closes.

On Friday, September 16, Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus’s commercialization rights to treosulfan, that the U.S. Food and Drug Administration (FDA) has delivered to medac a second notice of incomplete response regarding medac’s new drug application resubmission for treosulfan (NDA).

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”).

The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA (www.cancerna.info), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.

Hummingbird Bioscience today announced that Jerome Boyd-Kirkup , Ph.D., Hummingbird Bioscience’s Chief Scientific Officer, will present at the 2nd Annual VISTA Symposium on September 23, 2022.

Viracta Therapeutics’ Board of Directors appoints Mark Rothera as President and Chief Executive Officer.